



STEALTH PEPTIDES DEVELOPMENT ROUNDUP

8 APRIL 2010, ROCKVILLE, MARYLAND – Stealth Peptides is a biopharmaceutical company developing novel and innovative mitochondrial targeted therapies for diseases with clear unmet medical needs including those within the cardiovascular, renal and metabolic areas.

Stealth has a rich and promising pipeline of preclinical and clinical compounds from a unique class of short peptides (500–700 Daltons each). The preclinical compounds for Stealth show promising pharmacokinetic and safety profiles from *in vivo* animal studies. Additionally, published data suggest significant *in vivo* and *in vitro* efficacy using standard metabolic models including those for diabetes.

Stealth recently filed an investigational new drug (IND) application with the U.S. FDA for Bendavia™, a compound that targets the mitochondria to treat ischemia reperfusion injury such as commonly associated with cardiovascular and renal insults. Stealth's IND is for acute myocardial infarction (AMI) and is focused on demonstrating translation of Bendavia's preclinical efficacy into patients.

Statistics from the American Heart Association indicate that more than 600,000 people within the U.S. die from heart disease and AMI each year, which is greater than the combined total from every type of cancer. The degree of infarcted tissue is a major determinant of mortality and morbidity with AMI. Bendavia has demonstrated the ability to significantly reduce infarct sizes (more than –35%) across several standard AMI models (*ex vivo* to large animals) when administered prior to the onset of reperfusion. Moreover, AMI mortality and morbidity risks are significantly increased for patients that are renally impaired, which is more than 50% of the AMI patient population.

Published *in vivo* data suggest that Bendavia is also a strong kidney protectant for a variety of renal insults. Bendavia has further demonstrated more than a 1,000 fold safety margin from efficacy to toxicity. Stealth is anticipating the initiation of U.S. Phase I studies with Bendavia during the second quarter of 2010.

More information regarding Stealth Peptides is available upon request. Please contact Travis Wilson, CEO, Stealth Peptides Incorporated, 155 Gibbs Street, Suite

431, Rockville, Maryland 20850, travis.wilson@stealthpeptides.com, for further details.